In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells.

N L Letvin; L V Chalifoux; K A Reimann; J Ritz; S F Schlossman; J M Lambert

doi:10.1172/JCI112625

Find articles by Letvin, N. in: PubMed | Google Scholar

Find articles by Chalifoux, L. in: PubMed | Google Scholar

Find articles by Reimann, K. in: PubMed | Google Scholar

Find articles by Ritz, J. in: PubMed | Google Scholar

Find articles by Schlossman, S. in: PubMed | Google Scholar

Find articles by Lambert, J. in: PubMed | Google Scholar

Published in Volume 78, Issue 3 on September 1, 1986
J Clin Invest. 1986;78(3):666–673. https://doi.org/10.1172/JCI112625.
© 1986 The American Society for Clinical Investigation

Published September 1, 1986 - Version history

The selective delivery in vivo of a T lymphocyte-specific monoclonal antibody and immunotoxin conjugates to T cells in lymph node and spleen was assessed in rhesus monkeys. A transient coating of all T lymphocytes in the lymph nodes and spleens of healthy rhesus monkeys could be achieved after infusion of unconjugated anti-T11. Because derivatized antibody is cleared more rapidly than unconjugated antibody, it was necessary to infuse a higher dose of immunotoxin than antibody alone to achieve saturation of the lymphocyte binding sites with anti-T11. When sufficient antibody-toxin conjugate was infused, toxin was readily demonstrable on lymph node and spleen T cells by 16 h after infusion. This demonstration that toxins can be successfully delivered with specificity to target T cell populations in the monkey suggests that killing of restricted cell populations in vivo should be feasible.

Images.